Background {#Sec1}
==========

The usefulness of antimicrobial combination therapy, such as the use of aminoglycosides in patients with severe sepsis or septic shock, remains controversial \[[@CR1], [@CR2]\]. Nevertheless, early and appropriate antimicrobial therapy in septic shock patients has been reported to reduce in-hospital mortality \[[@CR2]\]. In view of this, aminoglycosides are often combined with another antibiotic in patients with severe sepsis or septic shock in order to broaden the treatment's spectrum of activity and obtain bactericidal synergy. The therapeutic effect of aminoglycosides is highest and optimal when the peak plasma concentration (*C* ~max~)/minimal inhibitory concentration (MIC) ratio is between 8 and 10 \[[@CR3]\]. However, in patients with severe sepsis or septic shock, aminoglycosides are frequently used in empiric antimicrobial treatment without the causal micro-organisms and their MICs being identified. The French guidelines recommend to use high doses of aminoglycosides for empiric antibiotic therapy in patients suffering from severe sepsis or septic shock, and, specifically, doses of 25--30 mg/kg in the case of amikacin \[[@CR4], [@CR5]\]. In clinical practice, the recommended target is an amikacin *C* ~max~ between 60 and 80 mg/L \[[@CR4]\], which corresponds to approximately 8--10 times the MIC breakpoint, as defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) of *Pseudomonas aeruginosa* and Enterobacteriaceae \[[@CR5]\]. Previous studies have shown that a loading dose of 25 mg/kg frequently leads to a suboptimal amikacin *C* ~max~ (\>30% of patients with *C* ~max~ \< 60 mg/L) \[[@CR6], [@CR7]\], prompting an increase in the loading dose to 30 mg/kg without improving outcomes \[[@CR8], [@CR9]\]. Yet the dose of 30 mg/kg has been evaluated in a limited number of patients (*n* \< 50) \[[@CR8], [@CR9]\]. The aim of this study was to assess the incidence and impact on mortality of an amikacin concentration between 60 and 80 mg/L in patients suffering from severe sepsis or septic shock.

Methods {#Sec2}
=======

The present observational study was approved by the Ethics Committee of Félix Guyon University Hospital (R15003). The requirement to obtain written informed consent from patients was waived, as the study was non-interventional and followed our usual protocol. However, all patients or their legally authorised representative was verbally informed about the process of data collection and could refuse to participate.

The reporting of this study complies with the Strengthening the Reporting of Observational studies in Epidemiology recommendations statement \[[@CR10]\].

Selection of the study sample {#Sec3}
-----------------------------

This prospective observational cohort study was conducted from April 2015 to December 2015 in one mixed medical/surgical ICU and in one surgical ICU at two French university hospitals.

All patients were over 18 years old and treated for severe sepsis or septic shock with a combination therapy of amikacin at a loading dose of 30 mg/kg (±2.5 mg/kg) on the day of enrolment.

The first dose of amikacin was calculated using the total body weight of the day for patients with a body mass index \<30 kg/m^2^. For patients with a body mass index ≥30 kg/m^2^, the dose was calculated using the adjusted body weight, which was calculated as follows: ideal body weight (height (cm) − 100 − \[height (cm) − 150\]/4 for male gender and height (cm) − 100 − \[height (cm) − 150\]/2 for female gender) + 0.4 \[total body weight at admission-ideal body weight\].

Severe sepsis and septic shock were defined following the Surviving Sepsis Campaign guidelines \[[@CR11]\].

Only the first day of amikacin administration was studied.

The prescribed duration of the continuous infusion was 30 min. Measurements of *C* ~max~ and trough concentration were taken 30 min and 24 h after the end of infusion. All samples were analysed immediately. Amikacin dosages were measured using a fluorescence polarisation immunoassay \[[@CR12]\].

Trough concentration was considered elevated if \>2.5 mg/L and was assessed only if treatment length was \>5 days or in cases of renal insufficiency, as recommended by French guidelines \[[@CR4], [@CR6]\].

The exclusion criteria were: treatment with amikacin within 7 days prior to inclusion; inappropriate dose of amikacin (\<27.5 or \>32.5 mg/kg); inappropriate duration of amikacin infusion (\<25 or \>35 min); and inappropriate delays in measuring the amikacin *C* ~max~ (\<20 or \>40 min after the end of infusion).

Data collected and study endpoint {#Sec4}
---------------------------------

Patient comorbidities at ICU admission were recorded on inclusion.

After administering the loading dose of 30 mg/kg of amikacin, the main endpoint was to evaluate the impact of the amikacin *C* ~max~ on the in-ICU mortality of patients with severe sepsis or septic shock.

Statistical analysis {#Sec5}
--------------------

Results were expressed as total number (percentage) for categorical variables and as median \[25th--75th percentiles\] for continuous variables. Continuous variables were compared using the Mann--Whitney test or the Kruskal--Wallis test, as appropriate. Categorical variables were compared using the Chi-square test or the Fisher's exact test, as appropriate. Risk factors for in-ICU mortality in bivariate analysis with *P* \< 0.1 were entered into a multivariate logistic regression analysis using backward selection with *P* \< 0.05.

We considered that 50 patients were needed in the non-survivors group to perform a multivariate analysis with ten variables \[[@CR13]\]. Based on an in-ICU mortality rate of 50% in patients with severe sepsis or septic shock \[[@CR6]\], we calculated that 100 patients had to be included in the study cohort for there to be a minimum of 50 patients in the non-survivors group. Collinearity between independent factors was investigated. When identified, the most clinically relevant factor was chosen for use in the multivariate model. A *P* value \<0.05 was considered significant. Analyses were performed using SAS statistical software (8.2, Cary, NC, USA).

Results {#Sec6}
=======

Study population {#Sec7}
----------------

Over the study period, 921 patients were hospitalised, of which 150 (16.3%) received amikacin for severe sepsis or septic shock. Among the latter, 40 were excluded: 15 had received aminoglycosides in the previous seven days; 15 had received an inappropriate dose of amikacin; and 10 had an incorrect *C* ~max~ measurement taken. The remaining 110 patients formed the cohort.

Patient characteristics on ICU admission and study inclusion are shown in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}.Table 1Baseline patient characteristics at intensive care unit admission and at inclusionCharacteristicsTotal (*n* = 110)Amikacin *C* ~max~ (mg/L)*P*\<60 (*n* = 20)60--80 (*n* = 46)\>80 (*n* = 44)At ICU admission Age (years old)61 \[51--70\]57. 5 \[50.5--69\]63 \[45--69\]62 \[55.5--70\]0.521 Male sex78 (70.9)14 (70)33 (71.7)31 (70.5)0.986 Weight (kg)70 \[58.2--80\]60 \[52.5--73.5\]70 \[58.2--80\]72.5 \[65--82\]0.029 Body mass index (kg/m^2^)24.6 \[20.7--28\]21.1 \[18.5--25.7\]23.7 \[20.8--27.3\]26.6 \[21.9--29\]0.023 APACHE II23 \[18--28\]25 \[21--28\]23 \[17--28\]22 \[18--26\]0.309 Simplified Acute Physiology Score 254 \[41--68\]62 \[47--70\]54 \[44--63\]52 \[40--67\]0.361 History of congestive heart failure12 (10.9)1 (5)8 (17.4)3 (6.9)0.177 Liver cirrhosis4 (3.6)02 (4.3)2 (4.5)0.63 Chronic obstructive pulmonary disease26 (23.6)5 (25)10 (21.7)11 (25)0.924 Chronic kidney disease requiring dialysis9 (8.2)1 (5)2 (4.3)6 (13.6)0.233 Cancer (\<3 months)16 (14.5)4 (20)10 (21.7)2 (4.5)0.051 Diabetes mellitus39 (35.5)7 (35)12 (26.1)20 (45.5)0.158 Immunodepression24 (21.8)6 (30)9 (19.6)9 (20.5)0.616At the day of aminoglycoside administration Day since admission1 \[0--5\]1 \[0--6\]0.5 \[0--5\]1.5 \[0--6.5\]0.834 Emergent surgery25 (22.7)9 (45)12 (26.1)4 (9.1)0.005 Sequential Organ Failure Assessment score10 \[8--11\]10 \[9--11\]10 \[7--12\]10 \[8--12\]0.950 Weight (kg)70 \[60--80\]66 \[55.5--79\]71 \[58.2--80\]72 \[65.5--82\]0.104 Weight gain since ICU admission (kg)0 \[0--3\]0 \[0--3\]0 \[0--2\]0 \[0--2\]0.847 Extracorporeal membrane oxygenation15 (13.6)4 (20)5 (10.9)6 (13.6)0.611 Catecholamines89 (80.9)16 (80)36 (78.3)37 (84.1)0.776 Norepinephrine (µg/kg/min)0.44 \[0.1--0.93\]0.88 \[0.11--1.64\]0.46 \[0.09--0.83\]0.41 \[0.11--0.81\]0.343 PaO~2~/FiO~2~ ratio177 \[122--264\]155 \[90--230\]203 \[140--289\]159 \[118--258\]0.234 Renal replacement therapy40 (36.4)12 (60)15 (32.6)13 (29.5)0.05 Glomerular filtration rate (mL/min)45 \[18.6--86.2\]22.1 \[0--90.4\]43.6 \[24.6--86\]49.7 \[22.5--83.9\]0.583 Lactate level (mmol/L)2.3 \[1.2--4\]2.7 \[1.5--4\]2.3 \[1.2--6.5\]1.7 \[1.2--3.2\]0.315 Platelet count (G/L)204 \[97--307\]170 \[84--218\]204 \[90--340\]230 \[141--325\]0.113 Hematocrit level (%)29.3 \[26--31.6\]30.3 \[26.8--32.7\]29.7 \[27.3--31.6\]27.7 \[25.3--31.1\]0.284 Leucocyte count (G/L)13.9 \[8.9--21\]14.1 \[7.1--17.7\]15.6 \[8.9--23.2\]13 \[9.2--20.3\]0.373 Glasgow Coma Scale score15 \[13--15\]15 \[13--15\]15 \[13--15\]15 \[13--15\]0.661 Bilirubin level (mg/dL)12 \[8--20\]12.5 \[9--20\]12 \[9--29\]12 \[7--19\]0.657 Prothrombin time (%)66 \[52--78\]66 \[57--78\]64 \[47--81\]67 \[57--78\]0.606 Proteinemia (g/L)56 \[47--63\]46.5 \[40.5--60.5\]55.5 \[49--64\]59 \[51--64.5\]0.007Results are expressed as the median \[25th--75th percentiles\] or *n* (%) as appropriate*APACHE* Acute Physiology and Chronic Health Evaluation, *C* ~max~ peak plasma concentration, *PaO* ~*2*~ */FiO* ~*2*~ partial pressure of oxygen in arterial blood/fraction of inspired oxygen Table 2Baseline patient characteristics at intensive care unit admission and at inclusion (survivors/non-survivors)CharacteristicsSurvivors (*n* = 64)Non-survivors (*n* = 46)*P*At ICU admission Age (years old)60 \[45--69\]63 \[57--73\]0.03 Male sex49 (76.6)29 (63)0.12 Weight (kg)70 \[60--80\]70 \[58--79\]0.84 Body mass index (kg/m^2^)24.6 \[20.7--27.8\]24.4 \[20.7--28\]0.58 APACHE II21 \[17--25\]26 \[22--29\]0.0007 Simplified Acute Physiology Score 252 \[41--60\]57 \[45--73\]0.05 History of congestive heart failure6 (9.4)6 (13)0.54 Liver cirrhosis04 (8.7)0.03 Chronic obstructive pulmonary disease15 (23.4)11 (23.9)0.96 Chronic kidney disease requiring dialysis4 (6.3)5 (10.9)0.38 Cancer (\<3 months) 11 (17.2)5 (10.9)0.35 Diabetes mellitus15 (23.4)24 (52.2)0.002 Immunodepression16 (25)8 (17.4)0.34At the day of aminoglycoside administration Day since admission1 \[0--5\]2 \[0--7\]0.32 Emergent surgery17 (26.6)8 (17.4)0.26 Sequential Organ Failure Assessment score9 \[7--10\]10 \[9--13\]0.004 Weight (kg)70 \[60--81\]70.5 \[60--80\]0.92 Weight gain since ICU admission (kg)0 \[0--2\]0 \[0--3\]0.62 Extracorporeal membrane oxygenation7 (10.9)8 (17.4)0.33 Catecholamines49 (76.6)40 (87)0.17 Norepinephrine (µg/kg/min)0.26 \[0.04--0.61\]0.83 \[0.41--1.65\]0.0002 PaO~2~/FiO~2~ ratio200 \[140--280\]147 \[103--259\]0.06 Renal replacement therapy19 (29.7)21 (45.7)0.09 Glomerular filtration rate (mL/min)53.5 \[29.7--90.4\]29.8 \[0--65.9\]0.008 Lactate level (mmol/L)1.7 \[1.2--3.1\]3.2 \[1.4--7\]0.01 Platelet count (G/L)205 \[105--339\]201 \[86--270\]0.47 Hematocrit level (%)29.2 \[26--31.3\]29.7 \[26--32.4\]0.54 Leucocyte count (G/L)15.6 \[9.4--22.3\]13.4 \[7.8--18.7\]0.22 Glasgow Coma Scale score15 \[14, 15\]15 \[12--15\]0.23 Bilirubin level (mg/dL)12 \[8--17\]145 \[9--26\]0.22 Prothrombin time (%)72 \[57--81\]60 \[47--75\]0.01 Proteinemia (g/L)58 \[49--64\]52 \[46--62\]0.1 Amikacin *C* ~max~ between 60 and 80 mg/L34 (53.1)13 (28.3)0.009Results are expressed as the median \[25th--75th percentiles\] or *n* (%) as appropriate*APACHE* Acute Physiology and Chronic Health Evaluation, *C* ~max~ peak plasma concentration, *PaO* ~*2*~ */FiO* ~*2*~ partial pressure of oxygen in arterial blood/fraction of inspired oxygen Table 3Sites of infection and isolated micro-organisms*N*Sites of infection110 Pulmonary57 Catheter9 Intra-abdominal13 Skin and soft tissue6 Urinary tract6 Other3 Unknown16 Bacteraemia32Isolated micro-organisms108Cocci24 *Staphylococcus aureus*13 Other staphylococci3 *Enterococcus* spp.5 *Streptococcus* spp.3Bacilli84 Enterobacteriaceae56 *Escherichia coli*15 *Enterobacter* spp.18 *Serratia marcescens*3 *Klebsiella* spp.14 Other Enterobacteriaceae6 *Pseudomonas aeruginosa*21 *Acinetobacter baumannii*2 Other bacilli5None36

The median age was 61 \[51--70\], the median Simplified Acute Physiology Score 2 at admission was 54 \[41--68\], and the median SOFA score on the day of amikacin administration was 10 \[8--11\]. The sources of infection were respiratory in 57 cases (51.8%), intra-abdominal in 16 cases (14.5%) and catheter related in 9 cases (8.2%). Bacteraemia was present in 32 cases (29.1%) (Table [3](#Tab3){ref-type="table"}).

The most frequently isolated bacteria were *P. aeruginosa* (19.1%), *Enterobacter* spp. (16.7%) and *Escherichia coli* (13.9%) (Table [3](#Tab3){ref-type="table"}).

Amikacin dosages {#Sec8}
----------------

The median dose of amikacin was 30 \[29.2--30.6\] mg/kg. Pharmacodynamic amikacin targets (60 mg/L \< *C* ~max~ \< 80 mg/L) were achieved in 46 of the 110 patients (41.8%). Forty-four of the 110 patients (40%) had a *C* ~max~ \> 80 mg/L, and 20 of the 110 patients (18.2%) had a *C* ~max~ \< 60 mg/L. No patient had a *C* ~max~ \< 30 mg/L (Table [4](#Tab4){ref-type="table"}).Table 4Amikacin pharmacokinetic/pharmacodynamic parametersVariable*n* = 110Dose (mg)2100 \[1800--2400\]Dose (mg/kg)30 \[29.2--30.6\]Peak plasma concentration (mg/L)75 \[66.1--86.1\]Patients with a peak concentration \>80 mg/L44 (40)Patients with a peak concentration between 60 and 80 mg/L46 (41.8)Patients with a peak concentration \<60 mg/L20 (18.2)Patients with a peak concentration \<30 mg/L0Trough concentration \>2.5 mg/L^a^51 (78.5)Results are expressed as the median \[25th--75th percentiles\] or *n* (%)^a^Trough concentration was not measured for 45 patients

Trough concentration was measured for 65 patients (68.2%). Among these, 51 (78.5%) had a trough concentration \>2.5 mg/L.

Prognosis {#Sec9}
---------

The in-ICU mortality rate was 41.8%. A univariate analysis revealed that the amikacin *C* ~max~ was not associated with a reduction in the in-ICU mortality rate (*C* ~max~ was 73.6 \[65.9--83.6\] mg/L in survivors and 81.9 \[66.5--89.7\] mg/L in non-survivors, *P* = 0.12).

The univariate analysis also showed that the in-ICU mortality rate was lower in the group of patients with a *C* ~max~ between 60 and 80 mg/L (28.3%) than in patients with a *C* ~max~ \> 80 mg/L (56.8%, *P* = 0.006).

Moreover, there was no statistically significant difference of mortality between the group of patients with a *C* ~max~ between 60 and 80 mg/L and the group of patients with a *C* ~max~ \< 60 mg/L (40%, *P* = 0.18).

The univariate analysis of trough concentration measurements in 75 of the 110 patients (68.2%) revealed that a higher amikacin trough concentration was not associated with a higher in-ICU mortality rate (5.2 \[2.3--10.4\] mg/L in survivors versus 8.6 \[4.2--14.3\] mg/L in non-survivors, *P* = 0.058).

The proportion of micro-organisms with a greater than usual amikacin MIC (i.e. non-fermenting Gram-negative bacilli) in non-survivors was similar to that in survivors (16 of 64 in survivors group versus 6 out of 46 in non-survivors group, *P* = 0.12).

The other risk factors found to be predictive of in-ICU mortality (based on a bivariate analysis with *P* \< 0.1) are exposed in Table [2](#Tab2){ref-type="table"}.

Following multivariate analysis, compared to a *C* ~max~ between 60 and 80 mg/L, *C* ~max~ \> 80 mg/L was associated with a higher probability of mortality (OR 95% CI 3.96 \[1.54--10.2\], *P* = 0.004), and *C* ~max~ \< 60 mg/L was not associated with a higher probability of mortality (OR 95% CI 1.92 \[0.46--8.24\], *P* = 0.4). The multivariate analysis also revealed that the factors independently associated with a higher mortality rate were a higher age (*P* = 0.02) and a higher norepinephrine dose (*P* = 0.0001) (Table [5](#Tab5){ref-type="table"}).Table 5Multivariate analysis of risk factors for in-intensive care unit mortalityVariablesAdjusted odds ratio (CI 95%)*P* valueAge (per year increment)1.044 (1.01--1.08)0.02Norepinephrine (per µg/kg/min increment)3.94 (1.9--8.15)0.0001Amikacin *C* ~max~ Between 60 and 80 mg/LReferenceReference \<60 mg/L1.92 (0.46--8.24)0.4 \>80 mg/L3.96 (1.54--10.2)0.004Prothrombin time0.98 (0.96--1.01)0.118PaO~2~/FiO~2~ ratio0.99 (0.99--1)0.28Diabetes mellitus1.6 (0.59--4.38)0.32Glomerular filtration rate (mL/min)0.99 (0.98--1.01)0.43Lactate level1.01 (0.89--1.14)0.53SOFA1.03 (0.81--1.3)0.18The Hosmer--Lemeshow goodness-of-fit test *P* value was 0.248. The Nagelkerke and Cox/Snell *R* ^2^ were, respectively, 0.347 and 0.258*CI* confidence intervals, *C* ~max~ peak plasma concentration, *PaO* ~*2*~ */FiO* ~*2*~ partial O~2~ pressure in arterial blood/fraction of the inspired oxygen ratio, *SOFA* Sequential Organ Failure Assessment

In survivors, acute kidney injury was not associated with a *C* ~max~ \> 80 mg/L (15.8% of patients who developed acute kidney injury had a *C* ~max~ \> 80 mg/L, while 14.2% who did not had a *C* ~max~ \> 80 mg/L, *P* = 0.88).

An amikacin trough concentration \>2.5 mg/L was not significantly associated with acute kidney injury (*P* = 0.26).

Discussion {#Sec10}
==========

To our knowledge, this is the largest study evaluating the incidence and impact on in-ICU mortality of an amikacin *C* ~max~ achieved with a high loading dose of 30 mg/kg. Roger et al. and Galvez et al. evaluated the effects of a dose of 30 mg/kg of amikacin in 47 and 33 patients, respectively, but did not assess the impact of amikacin concentration on mortality \[[@CR8], [@CR9]\]. In these studies, the median *C* ~max~ obtained with a loading dose of 30 mg/kg of amikacin was 75 mg/L. This is consistent with previous studies that reported values ranging from 72.1 to 75.8 mg/L \[[@CR8], [@CR9]\]. We found that, with a loading dose of 30 mg/kg of amikacin, the pharmacodynamic *C* ~max~ target (i.e. \>60 mg/L for the less susceptible bacteria) was frequently achieved (81.2% cases), a rate that is consistent with previous studies \[[@CR8], [@CR9]\].

Studies by Taccone et al. \[[@CR7]\] and de Montmollin et al. \[[@CR6]\], in which amikacin concentration following a loading dose of 25 mg/kg was evaluated, found a high frequency of underdosing (\>30%). These results prompted an increase in the loading dose of amikacin with the aim of achieving a *C* ~max~ \> 60 mg/L in the highest number of patients \[[@CR8], [@CR9]\].

In our study, the amikacin *C* ~max~ between 60 and 80 mg/L recommended by French guidelines \[[@CR4]\] was associated with a reduction in the in-ICU mortality rate. In theory, a *C* ~max~ of amikacin between 60 and 80 mg/L would be optimal for treating sepsis caused by less susceptible Enterobacteriaceae and non-fermenting Gram-negative bacterial infections (such as *P. aeruginosa*) with a MIC of 8 mg/L. This is highlighted in a study by Dubois et al. \[[@CR14]\], in which 61% of the isolated *P. aeruginosa* strains had a MIC of 8 mg/L. However, in patients with severe sepsis or septic shock, aminoglycosides are frequently used in empiric antimicrobial treatment without the causal micro-organisms and their MICs being identified. One of the major potential advantages of using aminoglycoside combination therapy is to broaden antibiotic treatment in cases of resistant bacteria, which may be found in ICUs \[[@CR15], [@CR16]\]. Combination therapy can increase the success of empiric therapy in up to 20% of patients \[[@CR17], [@CR18]\]. A high *C* ~max~ is therefore likely necessary given that *P. aeruginosa* is one of the most frequently isolated micro-organisms, even in cases of early-onset sepsis \[[@CR19], [@CR20]\].

We agree with Roger et al. \[[@CR8]\] that a lower amikacin *C* ~max~ may be enough to treat sepsis. In their study, all isolated strains had an amikacin MIC ≤ 4 mg/L, meaning that a *C* ~max~ between 32 and 64 mg/L would be sufficient to meet pharmacokinetic/pharmacodynamic parameters in all patients (i.e. *C* ~max~/MIC \> 8) \[[@CR8]\]. In the present study, we found that with a high dose of 30 mg/kg of amikacin, *C* ~max~ \> 80 mg/L was frequently observed and was associated with higher mortality rates. We did not identify a clear hypothesis to explain the relationship between amikacin concentration \>80 mg/L and mortality. Similar mortality results were found in a small randomised study of 99 patients by Galvez et al. \[[@CR9]\] compared three dosing regimens (15, 25 and 30 mg/kg) of amikacin in patients with severe sepsis or septic shock. In the 15, 25 and 30 mg/kg amikacin-treated groups, the study found that a *C* ~max~ \> 60 mg/L was reached in 0, 39 and 76% of patients, respectively, but the mortality rate was 0, 9.1 and 22.2%, respectively. This study was not, however, designed to statistically analyse mortality. We found that patients with amikacin overexposures tended to have greater amikacin trough concentrations (*P* = 0.08). It is well established that aminoglycosides are associated with nephrotoxicity \[[@CR21], [@CR22]\], and that a high amikacin *C* ~max~ in ICU is associated with higher trough-level concentrations \[[@CR6]\]. Nevertheless, it is difficult to consider these high *C* ~max~ as "overexposure" and further studies are needed. Moreover, recent in vitro and in vivo studies suggest that higher aminoglycosides exposure should be targeted for difficult to treat pathogens \[[@CR23], [@CR24]\]. To date, there is a lack of data on aminoglycoside-related toxicity in once-daily dose and short-duration aminoglycoside therapy. The present study was not designed to analyse and evaluate the association between acute kidney injury and trough concentration or aminoglycoside *C* ~max~, in that trough concentrations were not measured in all patients, as suggested by French guidelines \[[@CR4]\]. Furthermore, previous studies suggest that aminoglycoside-associated acute kidney injury cannot be solely attributed to aminoglycosides, because other factors are frequently associated with acute kidney injury in the ICU, including sepsis, septic shock or nephrotoxic drugs \[[@CR25], [@CR26]\].

Despite the current trend to increase doses of antibiotics in ICUs for pharmacokinetic/pharmacodynamic purposes, no beneficial effect on outcome has been clearly demonstrated \[[@CR6]--[@CR8]\]. In clinical practice, in Europe physicians are still using low doses of aminoglycosides, as shown by a recent survey of antimicrobial prescribing practices in ICUs, where aminoglycosides were administered at "low" doses (5 mg/kg for gentamicin and 15 mg/kg for amikacin) \[[@CR27]\].

This study has severe limitations. Given that it was not a randomised controlled trial comparing different loading regimens, we cannot conclude a direct causal relationship between the amikacin *C* ~max~ and the mortality rate. We did not evaluate the subsequent amikacin *C* ~max~ after the first injection of the study, and MIC of isolated bacteria was not determined for amikacin. Although the study population may be considered small, to our knowledge this is the largest cohort to have been selected for evaluating the impact of high doses of 30 mg/kg of amikacin in patients with severe sepsis or septic shock \[[@CR8], [@CR9]\]; moreover, other studies confined their analysis to pharmacokinetics/pharmacodynamics parameters \[[@CR8], [@CR9]\]. We agree that analysing pharmacokinetics/pharmacodynamics parameters of medications is one of the first steps before launching an impact study \[[@CR28]\]. Nevertheless, aminoglycosides are associated with well-known and severe side effects and analysing outcomes when increasing usual doses is indispensable. Previous studies reported that when high doses of aminoglycosides are administered, sampling within 90 min of the infusion provides information that leads to the overestimation of the peak serum concentration/minimum inhibitory concentration ratio and to the inaccurate calculation of pharmacokinetic parameters \[[@CR29], [@CR30]\]. Nevertheless, these studies were confined to gentamicin concentrations in a limited number of healthy volunteers (\<13) \[[@CR29], [@CR30]\]. By contrast, recent studies \[[@CR6]--[@CR10]\] have reported measurements of amikacin *C* ~max~ performed 30 min after infusion, as suggested by French guidelines \[[@CR4]\].

Conclusion {#Sec11}
==========

This study suggests that with a high loading dose of 30 mg/kg the amikacin *C* ~max~ between 60 and 80 mg/L recommended by French guidelines is associated with reduced in-hospital mortality, but that it is difficult to achieve in ICU patients (\<50%). Amikacin overexposure (i.e. *C* ~max~ \> 80 mg/L) was frequent and potentially associated with increased mortality.

APACHE

:   Acute Physiology and Chronic Health Evaluation
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:   peak plasma concentration

ICU

:   intensive care unit
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:   Simplified Acute Physiology Score
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:   Sequential Organ Failure Assessment
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